This study is designed to assess the efficacy and safety of OCH-NCNP1 compared to placebo in
subjects diagnosed with relapsing remitting multiple sclerosis (RRMS) and secondary
progressive mltiple sclerosis (SPMS) .
Phase:
Phase 2
Details
Lead Sponsor:
National Center of Neurology and Psychiatry, Japan